Viatris and Medical Learning Hub welcome you to the live CME on Enhance meetings III : The Courtroom Series ; an interactive, debate-style program that uses a courtroom format to simplify key clinical dilemmas in Hepatitis B management. Through two case dockets, expert faculty present opposing viewpoints supported by polling, rebuttals, and focused discussions.
The session explores critical questions on the duration of NA therapy and the approach to universal versus selective treatment in HBsAg-positive patients, followed by an interactive Q&A. This format delivers clear, evidence-based insights and enhances decision-making in HBV care.
To know more click Agenda.
We wish you a great learning experience!
We thank Mylan Pharmaceuticals Private Limited, a Viatris Company for supporting us in the webinar
|
Topic
|
Details
|
Faculty
|
Time slot
|
|
Welcome and
Introduction
|
|
Viatris/MLH
|
5 min
|
|
Context to Case
docket 1
|
|
Viatris
|
5 min
|
|
Courtroom Case
docket 1 - Duration of NA Therapy – with polling
|
Position A -
Continue indefinitely to suppress HBV DNA & reduce HCC risk
|
Dr. (Prof.) Anil
Arora
|
20min
|
|
Position B - Stop
after years of suppression (esp. with HBeAg seroconversion, low HBsAg, or
APASL criteria)
|
Dr. Krishnadas
Devadas
|
|
Rebuttal
|
Position A
|
Dr. (Prof.) Anil
Arora
|
5 min
|
|
Context to Case
docket 2
|
|
Viatris
|
5 min
|
|
Courtroom Case
docket 2 - Universal Treatment vs. Selective – with Polling
|
Position A - Treat
all HBsAg+ patients to reduce HCC/transmission risk
|
Dr. (Prof.) Anil
Arora
|
20 min
|
|
Position B - Treat
only those with active disease or cirrhosis
|
Dr. Krishnadas
Devadas
|
|
Rebuttal
|
Position A
|
Dr. (Prof.) Anil
Arora
|
5 min
|
|
Question and Answer
|
|
All Faculty
|
10 min
|
|
Vote of Thanks
|
|
Viatris / MLH
|
5 min
|
